GlassScriptPhysician profile
Gary Todd Midelton
NPI 1891882262
$3,377.89
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,785 · 2020: $376 · 2021: $231 · 2022: $277 · 2023: $686 · 2024: $22.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,215.39 | 2019-2023 | Farxiga, Breztri |
| Lilly USA, LLC | $198.58 | 2020-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.35 | 2020-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $154.25 | 2022-2023 | |
| Gilead Sciences, INC. | $153.49 | 2019-2021 | |
| Novo Nordisk INC | $136.00 | 2022-2024 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $123.75 | 2020 | |
| Idorsia Pharmaceuticals US INC | $122.91 | 2023 | Quviviq |
| Exact Sciences Corporation | $24.86 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $21.30 | 2022 | |
| Redhill Biopharma INC. | $19.70 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.76 | 2022 | |
| Horizon Therapeutics Plc | $15.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Midelton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.